These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Development of the risk-based, phased-in approach for the international harmonization of the regulation of container closure systems for drugs in Taiwan. Chang LC; Kang JJ; Gau CS Regul Toxicol Pharmacol; 2016 Jun; 77():252-6. PubMed ID: 27016398 [TBL] [Abstract][Full Text] [Related]
46. Intravenous infusion bottle plugs as a source of microbial contamination. Holmes CJ; Allwood MC J Hyg (Lond); 1976 Dec; 77(3):315-20. PubMed ID: 826586 [TBL] [Abstract][Full Text] [Related]
47. PDA presentation at FDA Open Conference on Sterile Drug Manufacturing. Parenteral Drug Association. J Pharm Sci Technol; 1994; 48(1):4-6. PubMed ID: 8004417 [No Abstract] [Full Text] [Related]
48. How One Might Experimentally Determine if Container Closure Systems and Their Components and Materials of Construction Contribute Elemental Impurities To Packaged Pharmaceutical Drug Products. Jenke D PDA J Pharm Sci Technol; 2019; 73(2):181-190. PubMed ID: 30232139 [TBL] [Abstract][Full Text] [Related]
49. A model particulate research laboratory: I. Characterization of glass for parenteral products. Scothorn WW; Roseman TJ; Hamlin WE Bull Parenter Drug Assoc; 1976; 30(3):105-17. PubMed ID: 1268429 [No Abstract] [Full Text] [Related]
50. [Insoluble contaminants in large-volume parenteral solutions. III. Effect of drug containers and sterilization]. Pawlaczyk J; Nowacka D Acta Pol Pharm; 1983; 40(2):199-206. PubMed ID: 6659998 [No Abstract] [Full Text] [Related]
51. A systematic approach for screening glass containers and elastomeric closures for use with parenteral solutions. White F; Koberda M; Chilamkurti R PDA J Pharm Sci Technol; 2008; 62(3):157-76. PubMed ID: 18661866 [TBL] [Abstract][Full Text] [Related]
55. Container Closure and Delivery Considerations for Intravitreal Drug Administration. Parenky AC; Wadhwa S; Chen HH; Bhalla AS; Graham KS; Shameem M AAPS PharmSciTech; 2021 Mar; 22(3):100. PubMed ID: 33709236 [TBL] [Abstract][Full Text] [Related]
56. Comparison of the Extraction Properties of Binary Polysorbate 80/Water and Isopropanol/Water Solutions for Organic Substances Originating from a Parenteral Infusion Pump. Zdravkovic SA PDA J Pharm Sci Technol; 2019; 73(6):588-614. PubMed ID: 31420503 [TBL] [Abstract][Full Text] [Related]
57. Residual Seal Force Testing: A Suitable Method for Seal Quality Determination of (High Potent) Parenterals. Buecheler JW; Luemkemann J; Gieseler H; Mohl S; Streubel A PDA J Pharm Sci Technol; 2019; 73(2):111-120. PubMed ID: 30361287 [TBL] [Abstract][Full Text] [Related]
58. Particulate contamination in New Zealand intravenous solutions. Passl WJ; Waring JM N Z Med J; 1980 Mar; 91(655):177-9. PubMed ID: 6929987 [TBL] [Abstract][Full Text] [Related]
59. A case study demonstrating the migration of diethyl phthalate from an ancillary component to the drug product. Singh G; Gollapalli R; Blinder A; Gallo F; Patel M J Pharm Biomed Anal; 2019 Feb; 164():574-580. PubMed ID: 30466025 [TBL] [Abstract][Full Text] [Related]
60. Sterile products: advances and challenges in formulation, manufacturing and regulatory aspects--a regulatory review perspective. Hussong D AAPS PharmSciTech; 2010 Sep; 11(3):1482-4. PubMed ID: 20845091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]